Aurion Biotech has launched its cell therapy Vyznova for serious eye disorder bullous keratopathy in Japan, its debut market, becoming an alternative to corneal replacement using donor tissue.

Eyecare giant Alcon has bought a majority stake in cell therapy start-up Aurion Biotech, replacing the company's chief executive, in the culmination of a months-long struggle for control.

In September 2024, Aurion announced the first global commercial launch of this technology, Vyznova™ (which includes ... About Aurion Biotech, Inc. Aurion Biotech’s mission is to restore ...

TOKYO, April 23, 2025--(BUSINESS WIRE)--Aurion Biotech, a clinical-stage regenerative medicine company whose mission is to restore vision to millions of patients, today announced the appointments ...

Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. Terms of the deal weren't disclosed. Aurion will operate as ...

Aurion Biotech has pushed out its CEO. Swiss healthcare company Alcon last week acquired a majority interest in Aurion, a clinical-stage startup in Seattle that is developing advanced cell ...

The company recently acquired a majority interest in Aurion Biotech, Inc. - a clinical-stage company developing advanced cell therapies to treat eye diseases. Additionally, Alcon inked a ...

Morningstar brands and products Company Portfolio ...

Key leadership appointments to accelerate global clinical development of AURN001, a transformational cell therapy for corneal endothelial disease Aurion Biotech is developing AURN001, an ...